This bill requires the Government Accountability Office (GAO), the federal government's independent watchdog agency, to conduct a comprehensive study on how prescription drug prices are used in payment and compensation agreements throughout the drug supply chain. The study will examine pricing-based payment structures between major players in the supply chain, including pharmacy benefit managers, drug manufacturers, wholesalers, pharmacies, and insurance plan sponsors, and will assess potential conflicts of interest that may incentivize the promotion of higher-priced drugs. The GAO must submit its findings and recommendations to Congress within two years of the bill's enactment, with no specific funding amount specified in the legislation. This bill is focused purely on transparency and information-gathering rather than implementing direct changes to drug pricing practices.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.